Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SC Ropharma's enterprise value is lei255 Mil.
SC Ropharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was lei56 Mil. Therefore, SC Ropharma's EV-to-EBITDA for today is 4.55.
The historical rank and industry rank for SC Ropharma's EV-to-EBITDA or its related term are showing as below:
BSE:RPH's EV-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.51 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SC Ropharma's PE Ratio (TTM) for today is calculated as:
SC Ropharma's share price for today is lei0.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SC Ropharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was lei-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SC Ropharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, SC Ropharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SC Ropharma EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SC Ropharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SC Ropharma's EV-to-EBITDA falls into.
SC Ropharma's current Enterprise Value is lei255 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SC Ropharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was lei56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SC Ropharma (BSE:RPH) has a EV-to-EBITDA of 4.55 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SC Ropharma.
Is SC Ropharma's EV-to-EBITDA too high?
SC Ropharma's current EV-to-EBITDA is 4.55. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.51. SC Ropharma's value of 4.55 is 56.7% below this industry median. Overall, SC Ropharma has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does SC Ropharma's EV-to-EBITDA compare to competitors?
SC Ropharma's EV-to-EBITDA of 4.55 can be compared against companies in the Healthcare Providers & Services industry. The industry median EV-to-EBITDA is 10.51. SC Ropharma's value of 4.55 is 56.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.51, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SC Ropharma's current EV-to-EBITDA of 4.55 is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SC Ropharma. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SC Ropharma's current EV-to-EBITDA is 4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SC Ropharma stock overvalued right now?
SC Ropharma (BSE:RPH) has a current EV-to-EBITDA of 4.55. The current EV-to-EBITDA is 4.55 and 56.7% below the Healthcare Providers & Services industry median of 10.51. SC Ropharma's overall GF Score™ is 66/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SC Ropharma (BSE:RPH), the current EV-to-EBITDA is 4.55 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SC Ropharma SA is engaged in the production, distribution, and Retail sale of pharmaceutical products in specialized stores. Its product portfolio comprises over 50 products in the form of tablets, powders, capsules, and syrups covering 21 therapeutic areas.
66GF Score
Get the complete analysis for BSE:RPH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RPH has been successfully added to your 
